Verve Therapeutics Inc. (VERV)
$11.13
$0.00 (0.00%)As on 25-Jul-2025 09:30EDT
Market cap
$994 Mln
Revenue (TTM)
$60 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
89,312,200
5 Years Aggregate
CFO
$-392.47 Mln
EBITDA
$-518.92 Mln
Net Profit
$-540.65 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Verve Therapeutics (VERV)
| 97.3 | -0.4 | 92.6 | 57.2 | -28.6 | -- | -- |
|
BSE Sensex*
| -9.0 | 2.5 | 3.4 | -6.4 | 6.7 | 8.0 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Verve Therapeutics (VERV)
| -59.2 | -28.0 | -47.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Verve Therapeutics (VERV)
|
11.1 | 994.0 | 59.6 | -181.0 | -349.7 | -36.9 | -- | 2.1 |
| 1.4 | 718.8 | 0.0 | -30.7 | -- | -25.4 | -- | 6.2 |
Shareholding Pattern
View DetailsAbout Verve Therapeutics (VERV)
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial,... an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. As of July 25, 2025, Verve Therapeutics, Inc. operates as a subsidiary of Ridgeway Acquisition Corporation. Read more
-
Co-Founder & Independent Chairman of the Board
Dr. Burt A. Adelman M.D.
-
Co-Founder & Independent Chairman of the Board
Dr. Burt A. Adelman M.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Verve Therapeutics (VERV)
What is the current share price of Verve Therapeutics Inc (VERV) Today?
The share price of Verve Therapeutics Inc (VERV) is $11.13 (NASDAQ) as of 25-Jul-2025 09:30 EDT. Verve Therapeutics Inc (VERV) has given a return of -28.63% in the last 3 years.
What is the current PB & PE ratio of Verve Therapeutics Inc (VERV)?
Since, TTM earnings of Verve Therapeutics Inc (VERV) is negative, P/E ratio is not available.
The P/B ratio of Verve Therapeutics Inc (VERV) is 2.10 times as on 25-Jul-2025, a 51 discount to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.47
|
0.99
|
|
2023
|
-4.85
|
1.62
|
|
2022
|
-7.56
|
2.16
|
|
2021
|
-14.93
|
4.96
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Verve Therapeutics Inc (VERV)?
The 52-week high and low of Verve Therapeutics Inc (VERV) are Rs 11.41 and Rs 2.86 as of 23-Jun-2026.
What is the market cap of Verve Therapeutics Inc (VERV)?
Verve Therapeutics Inc (VERV) has a market capitalisation of $ 994 Mln as on 25-Jul-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Verve Therapeutics Inc (VERV)?
Before investing in Verve Therapeutics Inc (VERV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.